| February 1 |
The LANCET Published ENDORSE, the Largest Multinational Study
Showing That the Majority of Hospitalized Patients Surveyed are at
Risk for VTE and Many do not Receive Recommended VTE Prophylaxis |
| February 1 |
Pooled Phase 3 Study of Nplate (Romiplostim) in Adult Patients with
Chronic ITP Published in The Lancet |
| February 1 |
New Findings Show Enbrel (etanercept) Significantly Reduced Levels
of C-Reactive Protein, a Marker of Inflammation, in Patients with
Moderate to Severe Plaque Psoriasis |
| February 1 |
MediciNova's MN-166 Reduces Persistent Black Hole Formation in
Multiple Sclerosis Patients |
| February 1 |
Obagi Medical Products' Solubilized Benzoyl Peroxide Provides
Clinically Significant Lesion Reduction for Mild to Moderately
Severe Acne |
| February 1 |
Data Demonstrate that Obagi Medical Products' Condition &
Enhance Skin Care System is an Effective Complement to Facial
Rejuvenation Procedures |
| February 1 |
Researchers Find Biological Factors That May Drive Prostate Tumor
Aggressiveness in African-American Men |
| February 1 |
Analytical Results for Women from Large Scale Clinical Trial MEGA
Study Employing the Hypercholesterolemia Drug Mevalotin®
Published |
| February 1 |
New Data for Achillion's Elvucitabine Demonstrate Drug's Safety,
Efficacy and Suitability for Combination Therapy in HIV-Infected
Patients |
| February 1 |
Prostate Cancer: Watchful Wait or Vaccinate? |
| February 1 |
NexMed Announces Presentation of Data at the 66th Annual Meeting of
the American Academy of Dermatology |
| February 1 |
Observational Data Show Transfusion Patterns in
Chemotherapy-Induced Anemia Patients Receiving
Erythropoiesis-Stimulating Agents |
| February 1 |
Neuro-Hitech Reports Cognitive Improvement From Phase Two Clinical
Trial of Huperzine A In Alzheimer's Disease Patients |
| February 1 |
Heart Disease Deaths Continue to Decline in American Women |
| February 1 |
Remicade-Treated Patients Experienced Rapid and Substantial
Improvement in Psoriasis in Critical Regions of Body |
| February 4 |
Clinical Data Reported on Celgene Compound Apremilast (CC-10004)
Evaluating Efficacy, Safety and Quality of Life Improvement for
Psoriasis Patients |
| February 4 |
NanoBio Corporation Presents Preclinical and Interim Clinical Data
on Topical Treatments for Herpes Labialis and Onychomycosis at AAD
2008 |
| February 4 |
IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study
Demonstrating Improved Survival Published in the Journal of
Clinical Oncology |
| February 4 |
BioLineRx Announces Positive Results From Phase 2a Trial of
BL-1020, a GABA-Enhanced Antipsychotic for the Treatment of
Schizophrenia |
| February 4 |
Oncolytics Biotech Inc. Announces Publication of Research on
Combination Reovirus and Radiation Therapy |
| February 4 |
ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion
on ENHANCE Trial |
| February 4 |
Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of
Chronic Plaque Psoriasis |
| February 4 |
Study Suggests Risperidone Long-Acting Injection Combined with
Standard Treatment Helped Delay Time to Relapse in Patients with
Bipolar Disorder |
| February 4 |
Oncolytics Biotech Inc. Announces Publication of Research on
Combination Reovirus and Radiation Therapy |
| February 4 |
Penwest Announces Results of Phase IIa Clinical Study of Nalbuphine
ER |
| February 4 |
PhytoMedical Bolsters Cancer Research Following Favorable Results |
| February 4 |
St. Jude Finds Risk Factors for Severe RSV Infection in
Immunocompromised Children |
| February 5 |
PTC Therapeutics Announces Publication of Preclinical Data in PNAS |
| February 5 |
Savient Reports Additional Positive Trial Data for Secondary
Endpoints from Puricase (pegloticase) Phase 3 Studies |
| February 5 |
ATryn(R) Meets Primary Endpoint |
| February 5 |
Forest Laboratories, Inc. Announces Positive Results of Memantine
Study of Once-Daily Formulation |
| February 5 |
Hollis-Eden Pharmaceuticals Presents Additional Data Demonstrating
Activity of Apoptone in Inducing Cancer Cell Death |
| February 5 |
Ceremed's Ostene Stops Bone Bleeding Without Added Risk of Surgical
Infection, New Study Finds |
| February 5 |
Avanir Announces Progress on Zenvia Development |
| February 5 |
Cleviprex Demonstrated Rapid, Precise Blood Pressure Control in
High-Risk Patients, According to New Analyses |
| February 5 |
Multiple Dose Clinical Trial of TorreyPines Therapeutics'
Tezampanel Demonstrates Compound is Safe and Well-Tolerated |
| February 5 |
Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via
Hydration of Red Blood Cells |
| February 5 |
John Wayne Cancer Institute Researchers Show that a Key Protein
Appears to Enable Spread of Melanoma to the Small Intestine |
| February 6 |
Artes Medical's 5-Year Safety and Efficacy Data Presented at the
American Academy of Dermatology Conference |
| February 6 |
Senesco Technologies Reports on Results of Preclinical Multiple
Myeloma Studies |
| February 6 |
Biovitrum and Symphogen have Successfully Completed Phase I
Clinical Trial with Recombinant Polyclonal Antibody |
| February 6 |
Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the
Development of Isosorbide Mononitrate Sustained Release Tablets |
| February 6 |
VIR201 Phase IIa Trial Results Now Published in Peer Reviewed
Scientific Journal – Human Vaccines |
| February 6 |
Leading Investigators Highlight Advances in Photodynamic Therapy at
the American Academy of Dermatology Annual Meeting |
| February 6 |
Nymox Announces Positive Results from New Multi-Center U.S. Study
of NX-1207 For BPH |
| February 6 |
Intercell’s Therapeutic Hepatitis C Vaccine Meets Primary
Endpoints in Phase II |
| February 6 |
Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect
in Mice |
| February 6 |
Dr. Neil Sadick Presents on Pyratine-6 at the Annual Meeting of the
American Academy of Dermatology |
| February 7 |
Data From Anthera's Plasma Trial to be Presented as Late Breaker at
American College Of Cardiology Scientific Sessions |
| February 7 |
ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the
2008 American Association for Cancer Research Annual Meeting |
| February 7 |
EpiCept Announces Encouraging Results of Phase II Trial for NP-1
Cream in Diabetic Peripheral Neuropathy |
| February 7 |
IDX899 Demonstrates Rapid and Profound Inhibition of HIV
Replication in a Phase I/II Clinical Trial in Treatment-Naive
HIV-Infected Patients |
| February 7 |
Pfizer Presents New Data from HIV/AIDS Portfolio at Conference on
Retroviruses and Opportunistic Infections |
| February 7 |
Genes as Time Machines |
| February 7 |
Merck's Isentress (raltegravir) Tablets in Combination with other
Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and
Increased CD4 Cell Counts Through 48 Weeks of Therapy in
Treatment-Experienced Adults |
| February 7 |
VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II
Trial |
| February 7 |
CASTLE Study Showed Similar Efficacy Between Once-Daily Reyataz
(atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir
at 48 Weeks in Previously Untreated HIV-Infected Adult Patients |
| February 7 |
Vicriviroc Demonstrates Potent and Sustained Viral Suppression
Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected
Patients |
| February 7 |
Bevirimat Data Presented at 15th Conference on Retroviruses and
Opportunistic Infections |
| February 7 |
EpiCept Announces Encouraging Results of Phase II Trial for NP-1
Cream in Diabetic Peripheral Neuropathy |
| February 7 |
Roche and Pharmasset To Present the R7128 Monotherapy Resistance
Profile |
| February 7 |
Theratechnologies Presents Additional Results from Its Tesamorelin
52-week Phase 3 study at the Conference on Retroviruses and
Opportunistic Infections |
| February 7 |
Ardea Biosciences Presents Preclinical Data Demonstrating Favorable
Resistance Profiles for Non-Nucleoside Reverse Transcriptase
Inhibitors for the Treatment of Human Immunodeficiency Virus |
| February 7 |
New 48-Week Efficacy and Safety Data Presented for Intelence
(etravirine) as Part of HIV Combination Therapy |
| February 7 |
GeoVax Labs, Inc.'s Promising HIV/AIDS Vaccine Trial Data Presented
at Retrovirus Conference |
| February 7 |
Novelos Therapeutics and MUSC Abstract Accepted for Presentation at
2008 AACR Annual Meeting |
| February 7 |
DNA Predicts Reaction to Drug That Fights Alcohol Dependence |
| February 7 |
Amdoxovir plus Zidovudine Demonstrates Potent Antiviral Activity in
HIV-Infected Patients |
| February 7 |
Positive Results from Phase III Trial of Gamunex in Patients with
CIDP |
| February 7 |
Sustained High Efficacy of Gardasil Against Precancerous Cervical
Lesions Confirmed in Longest Follow-up of Large Phase III Studies |
| February 7 |
Inhibitex HIV Integrase Inhibitor Data Presented at 15th Annual
Conference on Retroviruses and Opportunistic Infections |
| February 7 |
QSB Anti-Virulence Platform Inhibits Biofilm Formation by
Staphylococcus Aureus MRSA and Candida sp |
| February 7 |
Alnylam Reports Pre-clinical Progress with RNAi Therapeutics in
Neurological Disease |
| February 7 |
Physicians Reconsider Implications of Enhance Trial |
| February 8 |
Labopharm Reports Positive Results for Phase III Study on
Once-daily Trazodone |
| February 8 |
American Heart Association Themed Issue Journal Report: Journal
Edition Dedicated to Women's Unique Hypertension Issues |
| February 8 |
InNexus Biotechnology Announces Preliminary Results of Animal Study
Comparing Cancer Killing Activity of Its DXL625 (CD20) Treatment
for Non-Hodgkin's Lymphoma With Leading Marketed Product |
| February 8 |
Aprotinin and Ace Inhibitors During Off-Pump Cardiac Surgery
Associated with Postoperative Renal Dysfunction |
| February 8 |
Human Activity and Climate Change Could Aid Spread of Flaviviruses |
| February 8 |
Discovery of New Gene Locus Associated with LDL-cholesterol Levels
Could Lead to New Treatments |
| February 8 |
Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab
Presented at Leading Symposium on Anti-Angiogenic Agents |
| February 8 |
InNexus Biotechnology Inc. To Host A Webcast Teleconference
Detailing Recent News on Royalty Pharma Agreement & Preliminary
Results of DXL625 Animal Study |
| February 8 |
Gene Variant Predicts Medication Response in Patients with Alcohol
Dependence |
| February 11 |
New Data Shows Davanat Extends Survival of End-Stage Colorectal
Cancer Patients More Than 6 Months |
| February 11 |
BioDelivery Sciences to Present BEMA Fentanyl Data at the 24th
Annual Meeting of the American Academy of Pain Medicine |
| February 11 |
Genetic Immunity Presents Clinical Data on DermaVir Patch Immune
Therapy at 15th Annual Conference on Retroviruses and Opportunistic
Infections |
| February 11 |
Bentley Pharmaceuticals Announces Completion of Treatment in Phase
II India Clinical Study in Type 2 Diabetes and Preliminary Clinical
Results |
| February 11 |
Pharmacyclics Announces Data and Publication Characterizing
Highly-Selective HDAC Inhibitor |
| February 11 |
Pixantrone Shows Activity in a Preclinical Study of Experimental
Autoimmune Myasthenia Gravis (EAMG) |
| February 11 |
Clavis Pharma Successfully Completes Clinical Phase I Study in
Haematology |
| February 11 |
Novel anti-CD20 monoclonal antibody ofatumumab demonstrates
anti-tumour responses in patients with relapsed/refractory B-cell
chronic lymphocytic leukaemia |
| February 11 |
Advanced Cell Technology Announces Presentation of Results from
Myoblast Study at ISCTR World Symposium |
| February 11 |
AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1
Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and
Enhances DNA Repair |
| February 11 |
AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of
Skin's Natural Antioxidant System |
| February 11 |
AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols
Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling |
| February 12 |
Compugen Announces In-Vivo Results for Two Novel Peptide Agonists
of MAS GPCR for Potential Treatment of Cardiovascular Pathologies |
| February 12 |
Micromet Announces the Publication of BiTE Antibody Review in Drugs
of the Future |
| February 12 |
Raven biotechnologies to Provide Updates on Oncology Pipeline With
Four AACR Presentations |
| February 12 |
Biovitrum has Completed an Exploratory Clinical Phase II Study in
Glaucoma |
| February 12 |
Ipsen: Clinical Update For Decapeptyl 6-Month Formulation in
Advanced Prostate Cancer |
| February 12 |
New Survey Shows African-Americans Are Concerned With Heart Health
but Unaware of Link to Brain Health |
| February 12 |
Hana Biosciences Announces Top-Line Phase 1 Clinical Trial Data
Demonstrating Alocrest to be Well-Tolerated With Promising
Anti-Tumor Activity |
| February 12 |
Depomed Reports Positive Efficacy Data From a Phase 2 Trial of
Gabapentin GR in the Treatment of Menopausal Hot Flashes |
| February 12 |
Valeant Pharmaceuticals Reports Positive Phase III Results for
Retigabine in RESTORE 1 |
| February 12 |
Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch
Comparable to Clinician-Applied Vaccine Patch |
| February 12 |
2008 is a Decisive Year for the Validation of the Asthma Target
Interleukin-13 |
| February 12 |
Patch Instead of Pills Makes Living with Alzheimer's Disease Easier |
| February 13 |
ARIUS Presents New Findings Showing Therapeutic Antibody Inhibits
Human Leukemic Cancer Stem Cells |
| February 13 |
DOR BioPharma Announces Positive New Pulmonary Effect Data from
orBec Clinical Trials |
| February 13 |
Cytheris Announces 48-Week Results of Phase I/II Study Showing
Administration of Interleukin-7 (IL-7) Significantly Improves CD4
T-Cell Counts in Chronically Infected HIV-1 Patients |
| February 13 |
Avado Study of Avastin Plus Docetaxel Chemotherapy Showed Improved
Progression-Free Survival in Patients With Advanced Breast Cancer |
| February 13 |
AVADO Study of Avastin Plus Docetaxel Chemotherapy Showed Improved
Progression-Free Survival in Patients with Advanced Breast Cancer |
| February 13 |
Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented
at the American Society for Clinical Oncology (ASCO) 2008
Genitourinary Cancer Symposium |
| February 13 |
Protox to Present Prostate Cancer Data at ASCO Conference |
| February 13 |
VEGF Neutralization Can Damage Brain Vessels, Say Schepens Eye
Research Institute Scientists |
| February 13 |
Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented
at the American Society for Clinical Oncology (ASCO) 2008
Genitourinary Cancer Symposium |
| February 13 |
Cytheris Announces 48-Week Results of Phase I/II Study Showing
Administration of Interleukin-7 (IL-7) Significantly Improves CD4
T-Cell Counts in Chronically Infected HIV-1 Patients |
| February 13 |
Publication of Data Concerning CAVATAK in Breast Cancer |
| February 13 |
Unique Treatment for Alzheimer's Disease Improves Behavioural
Symptoms for Patients - Ebixa Can Provide Benefits Alone or in
Combination |
| February 13 |
Marshfield Clinic Discovers Gene Variant Which Will Significantly
Enhance the Accuracy of Molecular Tests for Warfarin Metabolism |
| February 14 |
Dendreon Presents Data Correlating the Cumulative Potency of
Provenge to Overall Survival |
| February 14 |
Elite Pharmaceuticals, Inc. to Present Clinical Data at the
American Academy of Pain Medicine's 24th Annual Meeting |
| February 14 |
Solagran Limited Announce Unexpected Efficacy of Ropren in Treating
Severe Alcoholism |
| February 14 |
Data from Two Pivotal Trials of Amrix, a New Once-Daily
Extended-Release Muscle Relaxant, Presented at the American Academy
of Pain Medicine Meeting |
| February 14 |
SJTRI Scientists Present Newest Research on Drug-Eluting Stents
(DES) |
| February 14 |
Cougar Biotechnology Presents Positive CB7630 Phase I and Phase II
Data at ASCO 2008 Genitourinary Cancers Symposium |
| February 15 |
Intra-Cellular Therapies Presents Data on Its Schizophrenia and
Cognition in Schizophrenia Programs at the 14th Biennial Winter
Workshop on Schizophrenia and Bipolar Disorders |
| February 15 |
Poniard Pharmaceuticals Announces Positive First-line Phase 1
Safety and Efficacy Data With Picoplatin in Metastatic Prostate
Cancer Patients |
| February 15 |
OncoGenex Reports Lead Drug Candidate OGX-011 Achieved Primary
Endpoint in Phase 2 Trial with Second-Line Chemotherapy for
Prostate Cancer |
| February 15 |
Medical Therapies Limited Announce Positive Interim Results From
Cuprindo Phase I Clinical Trials |
| February 15 |
Cell Genesys Reports Association Between Immune Response and
Patient Survival in Phase 2 Trial of GVAX Immunotherapy for
Prostate Cancer |
| February 15 |
Medical Therapies Limited (ASX:MTY) Announce Positive Interim
Results From Cuprindo Phase I Clinical Trials |
| February 15 |
Oncoproteins Double-Team and Destroy Vital Tumor-Suppressor |
| February 15 |
Novel Approach Strips Staph of Virulence |
| February 15 |
Higher Body Mass Index Means Higher Risk of Several Cancers |
| February 15 |
Cougar Biotechnology Announces Presentation of Positive CB7630
Phase I Clinical Data at ASCO 2008 Genitourinary Cancers Symposium |
| February 19 |
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in
Patients With Non-Small Cell Lung Cancer |
| February 19 |
Nanoviricides Found Highly Effective Against Ebola by USAMRIID |
| February 19 |
Advanced Life Sciences Announces Successful Thorough QT Study of
Cethromycin |
| February 19 |
Drug Reduces Airway Mucus in Preclinical Asthma Model |
| February 19 |
Plexxikon Announces Publication of Key Data Demonstrating Possible
Personalized Medicine for a Variety of Cancers |
| February 19 |
Callisto Announces Guanilib Presentation at the 5th Annual Meeting
of Cancer Drugs Research and Development |
| February 19 |
InNexus Biotechnology Announces Second Preclinical CandidateDXL702
(HER2/neu) Targeting Breast Cancer |
| February 19 |
Can-Fite Initiated Phase I Clinical Trial With CF102 First Cohort
Was Successfully Completed |
| February 19 |
JADO Reports Clinical Proof of Concept With Raft Modulator in
Atopic Dermatitis |
| February 19 |
Giaconda - Clinical Phase Pilot Study Results |
| February 20 |
Antigenics Announces Publication of Phase 3 Melanoma Study Results
in Journal of Clinical Oncology |
| February 20 |
Phase I and Phase I/II DCVax-Brain Data Continues to Show
Significantly Improved Survival Rates for Brain Cancer Patients |
| February 20 |
Plexxikon Announces Publication of Key Data Demonstrating Possible
Personalized Medicine for a Variety of Cancers |
| February 20 |
Acrux Reports Compelling Results of Market Research on Testosterone
MD-Lotion |
| February 20 |
Sirtris Pharmaceuticals Co-Founder Presents First In-Vivo,
Preclinical Data Showing SIRT1 Activation Can Suppress Tumor
Formation and Growth |
| February 20 |
Smoking's Effects on Genes May Play a Role in Lung Cancer
Development and Survival |
| February 20 |
Bausch & Lomb Announces Positive Clinical Results for Zylet in
a Comparison of Safety and Efficacy with Tobradex in the Treatment
of Blepharokeratoconjunctivitis |
| February 20 |
Stress Hormone Impacts Memory, Learning in Diabetic Rodents |
| February 20 |
Nymox's NX-1207 Offers a New and Attractive Approach to the
Treatment of Benign Prostatic Hyperplasia |
| February 20 |
Novocell Reports Successful Use of Stem Cells to Generate Insulin
in Mice |
| February 21 |
StemCyte Presents Six Abstracts on the Applications of
Plasma-Depleted Umbilical Cord Blood Stem Cell Products at BMT
Tandem Meetings |
| February 21 |
Bionovo Announces Positive Developments in On-going Phase 1/2
Cancer Drug Trial |
| February 21 |
Pre-Clinical Data Show Intracellular Pathways Affected by Onconase |
| February 21 |
Dr. Mark Nestor Presents on Pyratine-6 at the South Beach Symposium |
| February 21 |
Advanced Cell Technology Demonstrates Efficient Generation of
Functional Hepatocytes (Liver Cells) From Human Embryonic Stem
Cells |
| February 25 |
Top-Line Results From Pivotal Phase 3 MEND-CABG II Clinical |
| February 25 |
Ipsen: Toremifene Citrate 80 mg Meets Primary and Key Secondary
Endpoints in Phase III Clinical Trial in Advanced Prostate Cancer
Patients on Androgen Deprivation Therapy |
| February 25 |
MacuSight Announces Positive Preliminary Results From Phase 1 Study
of Sirolimus in Wet Age-Related Macular Degeneration |
| February 25 |
Orion OYJ: GTx Announced Phase III Clinical Data for Toremifene
Citrate 80 mg |
| February 25 |
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in
Phase III Trial in Advanced Prostate Cancer Patients on Androgen
Deprivation Therapy |
| February 25 |
Publication of Data concerning Cavatak and Evatak in Prostate
Cancer |
| February 25 |
CV Therapeutics Announces Presentations at the American College of
Cardiology 57th Annual Scientific Session |
| February 25 |
Elixir Pharmaceuticals Presents New Data on Ghrelin Inhibition at
Keystone Meeting |
| February 25 |
NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule
Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer
Drugs Research & Development Conference |
| February 25 |
Idenix Announces Data Presentations at the 43rd Annual Meeting of
the European Association for the Study of the Liver (EASL) |
| February 25 |
ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study
of Xibrom Combination Therapy with Lucentis |
| February 25 |
Oncothyreon's PX-478 is Effective in Preclinical Model of Human
Lung Cancer |
| February 26 |
ARIUS Announces Five Abstracts Selected for Presentation at 2008
AACR Annual Meeting |
| February 26 |
Bradmer Announces Phase II Results Published in Newly Diagnosed
Glioblastoma which Demonstrate Improved Survival and Support
Upcoming Phase III Study |
| February 26 |
Lux Biosciences to Provide Update on Four Pipeline Programs,
Including Two Phase 3 Clinical Programs, at ARVO |
| February 26 |
Prana Announces Success in Phase IIa Clinical Trial of PBT2 in
Early Alzheimer's |
| February 26 |
Oral Talactoferrin Alfa Improves Overall Survival in Patients With
Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results
Presented at the 8th Annual Targeted Therapies for the Treatment Of
Lung Cancer Meeting |
| February 26 |
Eurand Announces Positive Pharmacokinetic Study Results of
Once-a-Day Ondansetron |
| February 26 |
Lixte Biotechnology Holdings, Inc. Announces Further Developments
Regarding the Anti-Cancer Activity of Its Patent-Pending
Proprietary Compounds |
| February 26 |
Data on PolyMedix Antimicrobial Polymers Presented at American
Society of Microbiology 6th Annual Biodefense and Emerging Diseases
Research Meeting |
| February 26 |
PrimeGen Biotech Announces Non-Viral Reprogramming of Human Cells
into Stem Cells |
| February 26 |
Pyratine-6 Study Published in Journal of Drugs in Dermatology |
| February 26 |
Faster Chemo Technique Increases Survival in Children with
Neuroblastoma |
| February 26 |
Nasal Vaccine for Smallpox Confers High Levels of Immunity Without
Safety Risks |
| February 26 |
Immunosyn Releases Wound Healing Photographs From the First Phase
'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers
With Biopharmeceutical SF-1019 |
| February 27 |
Oculus Innovative Sciences Announces Positive Top-Line Phase II
Data with Microcyn Technology in Mildly Infected Diabetic Foot
Ulcers |
| February 27 |
Nasal Vaccine for Smallpox Confers High Levels of Immunity Without
Safety Risks |
| February 27 |
Intercell Completes Phase I Clinical Trial for an Improved Seasonal
Influenza Vaccine Formulated with IC31 |
| February 27 |
Oculus Innovative Sciences Schedules Conference Call Today to
Discuss Positive Top-Line Phase II Data with Microcyn(R) Technology
in Mildly Infected Diabetic Foot Ulcers |
| February 27 |
Teens with Treatment-resistant Depression More Likely to Get Better
with Switch to Combination Therapy |
| February 28 |
XenoPort and GlaxoSmithKline Report Positive Top-Line Results of
Final Pivotal Trial of XP13512/GSK1838262 for Restless Legs
Syndrome |
| February 28 |
NeurogesX Announces Preliminary Results from Second Phase 3
Clinical Trial in HIV-DSP |
| February 28 |
Athersys Announces Summary Results for Phase 1 Safety Study of Its
Novel Obesity Drug |
| February 28 |
Dr. Gabriel Sosne to Present New TB4 Anti-Inflammation Data at ARVO |
| February 28 |
Everolimus (RAD001) Significantly Extends Progression-Free Survival
in Advanced Kidney Cancer Patients After Failure of Other Targeted
Therapy |
| February 28 |
PAION's Anticoagulant Solulin Successfully Tested in First-in-man
Study |
| February 28 |
Intravenous Immunoglobulin Treatment is Associated with a Reduced
Risk of Developing Alzheimer's Disease and Related Disorders |
| February 28 |
Biothera Drug Synergistic with Avastin Against Cancer, Study Finds |
| February 28 |
NeoStem Reports Positive Stem Cell Industry Research Trends From
The Journal of the American Medical Association and Third Annual
Stem Cell Summit |
| February 29 |
Inhibiton Therapeutics' Testing of ICA-1 Compound Continues to
Progress |
| February 29 |
Avontec Announce Results of a Multiple Dose Clinical Proof of
Concept Study with Its Drug Candidate AVT-01 Decoy ODN in Asthmatic
Patients |
| February 29 |
Alnylam Achieves First Human Proof of Concept for an RNAi
Therapeutic with GEMINI Study |
| February 29 |
Genetic Variation Associated with Treatment Response in a Clinical
Study of a New Atypical Antipsychotic Fiaptatm (iloperidone) |
| February 29 |
Liver Phase I Abstract Presented at 8th World Congress of IHPBA |
| February 29 |
InvestBio Portfolio Company Presents Phase I/II Trial Results of
Vaccine for Leukemia at American Society of Hematology Annual
Meeting |
| February 29 |
Mayo Researchers Look for Explanation Behind High Incidence of
Diabetes Among Asian Indians |
